JPWO2020205331A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020205331A5
JPWO2020205331A5 JP2021557602A JP2021557602A JPWO2020205331A5 JP WO2020205331 A5 JPWO2020205331 A5 JP WO2020205331A5 JP 2021557602 A JP2021557602 A JP 2021557602A JP 2021557602 A JP2021557602 A JP 2021557602A JP WO2020205331 A5 JPWO2020205331 A5 JP WO2020205331A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
polypeptide sequence
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527173A5 (https=
JP2022527173A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/024432 external-priority patent/WO2020205331A1/en
Publication of JP2022527173A publication Critical patent/JP2022527173A/ja
Publication of JPWO2020205331A5 publication Critical patent/JPWO2020205331A5/ja
Publication of JP2022527173A5 publication Critical patent/JP2022527173A5/ja
Pending legal-status Critical Current

Links

JP2021557602A 2019-03-29 2020-03-24 ヒト化抗クローディン18.2キメラ抗原受容体及びその使用 Pending JP2022527173A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962825955P 2019-03-29 2019-03-29
US62/825,955 2019-03-29
US201962859843P 2019-06-11 2019-06-11
US62/859,843 2019-06-11
US201962896758P 2019-09-06 2019-09-06
US62/896,758 2019-09-06
PCT/US2020/024432 WO2020205331A1 (en) 2019-03-29 2020-03-24 Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof

Publications (3)

Publication Number Publication Date
JP2022527173A JP2022527173A (ja) 2022-05-31
JPWO2020205331A5 true JPWO2020205331A5 (https=) 2022-06-29
JP2022527173A5 JP2022527173A5 (https=) 2022-06-29

Family

ID=72667032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557602A Pending JP2022527173A (ja) 2019-03-29 2020-03-24 ヒト化抗クローディン18.2キメラ抗原受容体及びその使用

Country Status (12)

Country Link
US (1) US20220184126A1 (https=)
EP (1) EP3947468A1 (https=)
JP (1) JP2022527173A (https=)
KR (1) KR20210144792A (https=)
CN (1) CN113784980B (https=)
AU (1) AU2020253792A1 (https=)
BR (1) BR112021016673A2 (https=)
CA (1) CA3132201A1 (https=)
IL (1) IL286696A (https=)
MX (1) MX2021011887A (https=)
SG (1) SG11202109052YA (https=)
WO (1) WO2020205331A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128502A1 (en) 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
WO2022122709A1 (en) * 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
CN115073606B (zh) * 2021-03-10 2025-05-02 上海莱馥医疗科技有限公司 一种靶向表达cldn 18.2的细胞的人源化嵌合抗原受体
CN113354739B (zh) * 2021-01-11 2022-08-23 上海莱馥医疗科技有限公司 一种靶向表达Claudin18.2细胞的嵌合抗原受体及其应用
CR20240124A (es) 2021-08-09 2024-08-06 Harbour Biomed Shanghai Co Ltd Anticuerpo dirigido contra cldn18.2, anticuerpo biespecífico y el uso de estos
AU2023276514A1 (en) * 2022-05-27 2024-12-05 Shenzhen Immunofoco Biotechnology Co., Ltd. Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof
US20240228610A9 (en) * 2022-10-10 2024-07-11 Medimmune, Llc Compositions and methods of treating cancer with chimeric antigen receptors targeting claudin 18.2
WO2025255276A1 (en) * 2024-06-04 2025-12-11 Fred Hutchinson Cancer Center Anti-whitlow linker binding domains and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014075788A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
AU2017294276B2 (en) * 2016-07-08 2024-08-01 Crage Medical Co., Limited Antibody for anti-claudin 18A2 and use thereof
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
JP7398380B2 (ja) * 2018-03-08 2023-12-14 フェインズ セラピューティクス,インコーポレーテッド 抗クローディン18.2抗体及びその使用

Similar Documents

Publication Publication Date Title
JP2021514664A5 (https=)
JP2022527173A5 (https=)
JPWO2019173420A5 (https=)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2022526420A5 (https=)
JP2021528047A5 (https=)
JP2022526841A5 (https=)
JP2020501531A5 (https=)
JP2009545325A5 (https=)
CN103189392B (zh) ErbB3结合抗体
JP2021511811A5 (https=)
WO2019042119A1 (zh) 抗人cd47抗体及其用途
CN103030695B (zh) 抗c‑Met人源化抗体及含其的预防或治疗癌症用的药物组合物
JP2013502913A5 (https=)
JP2013165711A5 (https=)
IL310938A (en) Anti-CCR8 antibodies and their uses
JP2016526904A5 (https=)
JPWO2019224711A5 (https=)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
TW200918556A (en) Treatment of tumors using specific anti-L1 antibody
JPWO2020210067A5 (https=)
JPWO2020205331A5 (https=)
CN109071671B (zh) Erbb2靶向抗体